Helen Kuo, MD
Urology · Meridian, IDNPI 1346407921
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,104 of the $5,456 with a category attached, or 75.2%. 33 manufacturers reported payments, led by SN Holdings, LLC at 30.1% of the total. Reporting peaked in 2023 at $2,394 and has fallen 50.3% since, to $1,189 in 2025.
Across 162 payments — averaging $33.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SN Holdings, LLC$2K
- Medtronic$618
- AbbVie$607
- Urogen Pharma, Inc.$285
- Johnson & Johnson$278
- Bayer$244
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,26023%
- Food & beverage$4,10475%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SN Holdings, LLC | 2 | $1,645 |
| Medtronic | 6 | $618 |
| AbbVie(2 entities) | 28 | $607 |
| Urogen Pharma, Inc. | 9 | $285 |
| Johnson & Johnson | 14 | $278 |
| Bayer | 10 | $244 |
| Merck | 12 | $240 |
| Sumitomo Pharma America, Inc. | 10 | $233 |
| Accord Healthcare, Inc. | 10 | $179 |
| Dendreon Pharmaceuticals LLC | 7 | $151 |
| Astellas Pharma US Inc | 4 | $132 |
| Endo USA, Inc. | 7 | $117 |
| Pfizer | 7 | $109 |
| Sanofi | 3 | $65 |
| Olympus America Inc. | 4 | $59 |
| AstraZeneca | 4 | $58 |
| Vertex | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 3 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $44 |
| Bluewind Medical | 1 | $39 |
| Immunitybio, Inc. | 2 | $36 |
| Laborie Medical Technologies Corp. | 1 | $29 |
| Foundation Medicine, Inc. | 2 | $28 |
| Amgen | 1 | $23 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Cardinal Health 414 LLC | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Agiliti Surgical, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Urogpo LLC | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,456 in reported general payments places this provider in the 80th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 245 | $171,890 |
| GemtesaVibegron | 34 | $27,770 |
| Methenamine Hippurate | 142 | $9,418 |
| Potassium Citrate ErPotassium Citrate | 34 | $5,943 |
| Trospium Chloride | 52 | $5,268 |
| Tamsulosin Hcl | 264 | $2,623 |
| Estradiol | 37 | $2,575 |
| Oxybutynin Chloride ErOxybutynin Chloride | 110 | $2,129 |
| Finasteride | 93 | $1,022 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $777 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 43 | $639 |
| Testosterone Cypionate | 15 | $596 |
| Testosterone | 11 | $442 |
| Cephalexin | 61 | $408 |
| Dutasteride | 12 | $292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $132 | $171,890245 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $233 | $27,77034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 55 urology providers in Idaho.
Other urology in Meridian
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Brian AugeMeridian$5K
- Michael JacobsonMeridian$4K
- Kara SaperstonMeridian$4K
- Joseph WilliamsMeridian$4K
- Lisa ParrilloMeridian$3K
- Michael TaylorMeridian$3K
- Jared HeinerMeridian$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.